Pancreatic Cancer

Virulizin shows activity against tumors in mouse model

Published in Cancer Weekly, April 22nd, 2003

Scientists at Lorus Therapeutics, Inc. have published the results of experimental studies in mouse models bearing human tumors treated with Virulizin, the company's lead anticancer immunotherapeutic drug.

Virulizin showed significant antitumor activity as a monotherapy and enhanced antitumor effects when used in combination with standard chemotherapy agents against a panel of human pancreatic tumors and melanoma.

Data describing the pharmacological activity of Virulizin as reported in Cancer Chemotherapy and Pharmacology, will be an important addition to the preclinical component of regulatory dossiers required to obtain marketing approval for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry